PubMed · 11249676
Technology evaluation: naked DNA.
Abstract
Vical and Merck are investigating vaccines against hepatitis B which use Vical's patented naked DNA technology. Both therapeutic and prophylactic vaccines are under development [177132], [268397]. The technology, and subsequent collaboration, stems from the observation by Vical that by directly injecting exogenous cDNA into muscle tissue, protein is expressed which gives rise to a strong immune response and protective immunity [163222].
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Y Ilan. 1999. Technology evaluation: naked DNA.. https://pubmed.ncbi.nlm.nih.gov/11249676/
Cite the original work for its findings. Save a collection to share your selection of sources.